# KLOW Peptide Dosage — Research Context for the Four-Component Blend

> KLOW peptide dosage context: the 80 mg vial composition, per-component research doses from animal studies, and the pharmacokinetic mismatch. Research use only.

## In plain English

KLOW peptide dosage has not been validated for humans. No clinical trial has tested the blend in people, so there is no established human dose — not for the combination and not for any of the four components in this context. What follows is the research-context information: the standard vial composition, the doses used in the animal and cell studies for each component, and the reasons why component doses cannot simply be added together. This is not a dosing guide.

## KLOW peptide dosage

The canonical research-vial composition across independent suppliers is 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. GHK-Cu is the mass-dominant component at 62.5% by mass.

No validated human dosing exists for the blend. The component-level research doses differ widely by species and route and do not translate to a single 'KLOW dose.' They are described per component below for research context only. None of this constitutes a dose recommendation.

## KLOW dosage

**TB-500 arm (thymosin beta-4):** In the Malinda 1999 wound-healing study, topical and IP thymosin beta-4 were active at very low amounts — as little as 10 pg was active in cell-migration assays [1]. In the Ruff 2010 Phase 1 trial of full-length synthetic thymosin beta-4 in humans, IV doses of 42, 140, 420 and 1260 mg were administered as single doses and then daily for 14 days; all four cohorts were well tolerated [8]. These are full-length native-protein doses, not TB-500 fragment doses.

**BPC-157 arm:** In rat Achilles tendon studies, IP doses of 10 microg, 10 ng and 10 pg per rat per day were tested; all three showed benefit versus untreated controls [2]. In the 2025 human IV pilot, 10 mg on day one and 20 mg on day two were the tested doses in two adults [6].

**GHK-Cu arm:** In cell-culture experiments, 1-10 nM drove transcriptomic and matrix-synthesis effects [4][5]. In the human hair-count trial, topical 50 mg/mL and 100 mg/mL formulations (combined with 5-ALA) were used over six months [11]. Human cosmetic topical applications vary widely by formulation.

**KPV arm:** In vitro activity at 10 nM. Oral KPV in mice at 100 microM in drinking water reduced colitis severity [3]. No approved human dose exists.

## KLOW peptide dosage and frequency

Frequency and duration contexts from the component literature:

**TB-500 arm:** The Ruff 2010 Phase 1 trial used daily dosing for 14 days at each dose level [8]. The Morris 2014 rat stroke study used IP dosing starting 24 hours post-event, then every three days for four more doses [10].

**BPC-157 arm:** Once-daily IP dosing in the Staresinic 2003 tendon study [2]. Typical reported research durations in the rodent literature run from days to weeks depending on the model.

**GHK-Cu arm:** The human hair-count trial ran for six months with daily topical application [11].

**KPV arm:** Continuous oral delivery in the drinking-water colitis model [3]. Duration not specified as a fixed protocol.

Pharmacokineticmismatch: the tripeptides KPV and GHK-Cu clear far faster than BPC-157 (reported half-life well under one hour in rodent PK studies for short peptides); the TB-500 fragment differs from full-length thymosin beta-4. A single co-formulated dose delivers all four simultaneously but cannot maintain matched exposures across the dosing window. This is a structural property of the blend, not a solvable formulation problem at standard reconstitution.

## Routes and stability

Routes studied in the component literature: subcutaneous injection (BPC-157 and thymosin beta-4), intraperitoneal injection (rat models for all four), topical application (GHK-Cu, thymosin beta-4), and oral/drinking-water delivery (KPV, BPC-157 in gut models). The KLOW research vial is supplied lyophilized (freeze-dried) and reconstituted with bacteriostatic water for laboratory handling.

A theoretical compatibility note: GHK-Cu contains a chelated copper(II) ion, which can participate in redox chemistry. Co-dissolving it with three other peptides in one solution raises a potential oxidation question that has not been formally characterized for this mixture [4][5]. Not a demonstrated stability failure — an uncharacterized variable.

---

A blueprint of the component literature — four peptides drawn against their own studies, the untested blend left as the one honest empty node.